| How innovative are pharmaceutical innovations? The case of medicines financed through add-on payments outside of the French DRG-based hospital payment system. | |
| | |
MedLine Citation:
|
PMID: 22136813 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
OBJECTIVE: To analyze the characteristics of inpatient medicines placed on the list of innovative high-cost medicines funded in addition to DRG-based payment, and to identify whether they really are innovative and/or high-cost. METHODOLOGY: The medicines placed on the list of innovative and high-cost medicines were analyzed on the basis of criteria describing their innovative nature and cost. They were categorized as innovative and high-cost, only high-cost, only innovative and neither innovative nor high-cost. RESULTS: Among the medicines financed in addition to DRG-based payment, 25.5% were classified as innovative and high-cost, 23.5% only high-cost, 22.9% only innovative and 28.1% neither innovative nor high-cost. CONCLUSIONS: The list of innovative and high-cost medicines contains medicines other than innovative and high-cost medicines. Stricter criteria for placing medicines on this list should be considered in order to limit the increase in expenditure. |
| | |
Authors:
|
Inna Gridchyna; Marine Aulois-Griot; Catherine Maurain; Bernard Bégaud |
Related Documents
:
|
18513673 - The value of feno measurement in asthma management: the motion for yes, it's no--or, th... 12478223 - The role of the case manager in a disease management program. 9613533 - The practice of peripheral nerve blocks in the united states: a national survey [p2e co... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-11-30 |
Journal Detail:
|
Title: Health policy (Amsterdam, Netherlands) Volume: - ISSN: 1872-6054 ISO Abbreviation: - Publication Date: 2011 Nov |
Date Detail:
|
Created Date: 2011-12-5 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8409431 Medline TA: Health Policy Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Copyright Information:
|
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved. |
Affiliation:
|
Droit et économie pharmaceutiques (DEPH), Université Bordeaux Segalen, 146 rue Léo Saignat, 33076 Bordeaux, France; Inserm U 657, 146 rue Léo Saignat, 33076 Bordeaux, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: From evidence assessments to coverage decisions? The case example of glinides in Germany.
Next Document: Measurements and standards for bulk-explosives detection.